TICKERNERD
Menu
CTKBCTKBHealthcare · Medical Devices

CTKB Stock Forecast: Cytek Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.81
+3.22% on the day

The 4 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $5 — +4.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$625.2M
Ticker Nerd rank
65 / 100
Median analyst target
$5.00
Analysts covering
4
Total return, dividends reinvested
1W
+2.6%
1M
+5.3%
YTD
−4.8%
1Y
+20.0%
From 52W high
−18.2%
From 52W low
+43.4%
$3.36
$5.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTKB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Volatility
77
Value
65
Momentum
59
Issuance
58
Quality
54
Size
51
Revisions
44
Growth
36

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTKB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26CTKBHigh $7.50Median $5.00Low $4.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
2 Buy2 Hold0 Sell
Low $4.75Median $5.00High $7.50

The green dot is the last close — the median target sits +4.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 May 2026Stephens & Co.MaintainsOverweight$5.50 → $4.75
12 May 2026Morgan StanleyMaintainsEqual-Weight$6.00 → $5.50
8 Jan 2026TD CowenMaintainsBuy—
11 Nov 2025Piper SandlerMaintainsOverweight—
28 May 2025Morgan StanleyMaintainsEqual-Weight—
12 May 2025Goldman SachsMaintainsSell—
19 Mar 2025Stephens & Co.ReiteratesOverweight—
4 Mar 2025Piper SandlerMaintainsOverweight—
11 Nov 2024Piper SandlerMaintainsOverweight—
13 Aug 2024Piper SandlerMaintainsOverweight—
13 May 2024Piper SandlerMaintainsOverweight—
6 Mar 2024Piper SandlerMaintainsOverweight—
29 Feb 2024Goldman SachsMaintainsBuy—
14 Dec 2023Stephens & Co.InitiatesOverweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
24 Oct 2023Morgan StanleyMaintainsEqual-Weight—
16 Oct 2023Piper SandlerMaintainsOverweight—
19 July 2023Raymond JamesInitiatesMarket Perform—
11 May 2023Morgan StanleyMaintainsEqual-Weight—
10 May 2023Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTKB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTKB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cytek Biosciences, Inc. (CTKB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
374.5×

Cheaper than 2% of US stocks

Price / sales
3.0×

Cheaper than 42% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
−9.3×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
5.6%

Higher than 40% of US stocks

Earnings growth (YoY)
5.6%

Higher than 42% of US stocks

Gross margin
58.9%

Higher than 73% of US stocks

Operating margin
−29.5%

Higher than 19% of US stocks

Net margin
−39.0%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−23.0%

Higher than 30% of US stocks

Return on assets
−6.3%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CTKB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CTKBCytek Biosciences, Inc.$625.2M
65
KIDSOrthoPediatrics Corp.$643.2M
62
DCTHDelcath Systems, Inc.$591.7M
96
SSIISS Innovations International, Inc.$694.1M
17
CERSCerus Corp.$539.8M
90
TCMDTactile Systems Technology, Inc.$537.3M
98
SENSSenseonics Holdings, Inc.$506.9M
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTKB news & analysis

Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

GlobeNewsWire · 21 Aug 2026neutral

A jury found in Cytek's favor on three of four asserted patent claims brought by Beckman Coulter, finding noninfringement and invalidity on those claims, but found infringement under the doctrine of equivalents on one claim and awarded $56 million in damages. Cytek plans to challenge the remaining finding through post-verdict motions.

Why it matters — The mixed verdict and $56 million damages award create uncertainty around a significant legal liability, while Cytek's plan to challenge the finding leaves the outcome unresolved.

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Cytek Biosciences, Inc.'s (CTKB) Q2 2026 earnings call. The item indicates the company held its quarterly earnings call and its transcript is now available.

Why it matters — A Cytek watcher would care because the earnings call transcript provides direct insight into the company's recent quarterly performance and management commentary.

Cytek Biosciences Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Cytek Biosciences reported second-quarter 2026 revenue growth of 6% year over year, driven by double-digit gains in the United States and China. Weaker sales in Europe and parts of Asia-Pacific limited the company's overall growth.

Why it matters — The results show balanced geographic performance for CTKB, with stronger markets offsetting regional weakness, which is relevant for investors tracking the company's revenue trajectory.

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

Cytek Biosciences reported a second-quarter loss of $0.05 per share, wider than the Zacks Consensus Estimate of a $0.02 loss, and compared with earnings of $0.01 per share in the same period last year. Revenue topped consensus estimates.

Why it matters — CTKB watchers would care because the company's quarterly loss came in well above analyst expectations and reversed a year-ago profit, signaling weaker-than-anticipated results for the period.

Cytek Biosciences Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026neutral

Cytek Biosciences, Inc. (Nasdaq: CTKB) reported its financial results for the second quarter ended June 30, 2026, announced on August 5, 2026. The company, described as a leading cell analysis solutions provider, released the results via a press release from its headquarters in Fremont, California.

Why it matters — A CTKB watcher would care because this quarterly financial report is a routine but important update on the company's recent operating performance.

FAQ

Frequently asked questions about CTKB stock

What is the CTKB stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $5, with estimates ranging from $4.75 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTKB stock a buy right now?

Of the 4 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTKB?

As at 22 Aug 2026, Cytek Biosciences, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will CTKB stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +4.0% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTKB stock forecast for 2030?

No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $7.5 over the next 12 months.

How has CTKB stock performed over the past year?

Cytek Biosciences, Inc. returned +20.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytek Biosciences, Inc. do?

Cytek Biosciences Inc. is a biotechnology company that specializes in advancing the capabilities of flow cytometry technologies.

What is the latest news on CTKB?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding". A jury found in Cytek's favor on three of four asserted patent claims brought by Beckman Coulter, finding noninfringement and invalidity on those claims, but found infringement under the doctrine of equivalents on one claim and awarded $56 million in damages. Cytek plans to challenge the remaining finding through post-verdict motions.

Company

About Cytek Biosciences, Inc.

Cytek Biosciences Inc. is a biotechnology company that specializes in advancing the capabilities of flow cytometry technologies. Its primary function is to develop and deliver transformative, cost-effective products for researchers and clinicians in the life sciences sector. The company is renowned for its full spectrum flow cytometry systems, which allow users to conduct high-parameter cell analysis with higher accuracy and efficiency compared to traditional methods. This technology has significant implications in numerous fields, including immunology, oncology, and stem cell research, thereby supporting efforts in drug discovery, clinical trials, and personalized medicine. Cytek Biosciences Inc.'s offerings play a crucial role in enabling scientific discoveries and advancing public health initiatives. As a prominent player in the biotechnology market, Cytek contributes to pushing the boundaries of what's possible in cellular analysis, fostering breakthroughs that can lead to new therapeutic strategies and medical treatments.

CEO Dr. Wenbin Jiang Ph.D. · 682 employees · United States · https://cytekbio.com